Table 3.

Selected repurposed drug candidates for giant cell arteritis treatment

	Target	Licensed indication
Abciximab	ITGB2B, ITGB3, VTN	Ischaemic cardiovascular events
Eptifibatide	ITGB3	Acute coronary syndrome
Tirofiban	ITGA2B, ITGB3	Acute coronary syndrome
Fostamatinib	CDK1, MELK, TTK	Chronic immune thrombocytopenia
Human C1 esterase inhibitor	KLKB1	Acute attacks of hereditary angioedema
Lanadelumab	KLKB1	Acute attacks of hereditary angioedema
Alteplase	FGA, PLG, PLAUR, SERPINE1	Lysis of acute massive pulmonary embolism, acute ischaemic stroke, and acute myocardial infarction
Anistreplase	FGA, PLG, SERPINE1	Lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction
Tenecteplase	FGA, PLG, PLAUR, SERPINE1	Myocardial infarction and lysis of intracoronary emboli
Urokinase	FGA, PLG, SERPINE1	Lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters
Reteplase	FGA, PLG, SERPINE1	Lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction
Streptokinase	PLG	Acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, or embolism and occlusion of arteriovenous cannulae

Only proposed candidate drugs are shown, the complete report of the drug repurposing analysis is provided in the appendix (pp 112–136).